First Keystone 3Q 2026: Revenue $12.67M, EPS $0.59 — 10-Q Summary

First Keystone reported 3Q 2026 revenue of $12.67M, up 11% YoY, with net income rising 33.2% to $3.74M. EPS increased to $0.59. Growth was driven by higher interest income and noninterest income, including service charges. Net interest margin improved to 2.73% from 2.64%.

Original reporting
Published Nov 12, 2026, 9:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
First Keystone 3Q 2026: Revenue $12.67M, EPS $0.59 — 10-Q Summary — source image
Decision brief

The 30-second read

$FKYSBullishLow
01

Why it matters

The earnings beat could attract short‑term buying interest, but the small scale limits broader market effect.

02

Market read

Micro‑cap earnings release with modest upside; limited broader market relevance.

03

What to watch

Potential credit risk from real‑estate loan exposure and modest loan growth.

Relevance 6/10Novelty 6/10Timing: after-hours release

Background

First Keystone Corp filed its Q3 2026 10‑Q, showing improved interest income and net income.

Company-level read

Ticker impact

$FKYSBullishHigh confidence
Context

First Keystone Corp reported Q3 2026 results with revenue $12.67M, EPS $0.59 and 33% net income growth.

Expected impact

likely modest upside as market prices in higher earnings and interest income

Evidence & confidence

The 33% net income increase and higher net interest margin are fresh, material data for a micro‑cap bank.

Market effects

Banking sector may see slight uplift from higher net interest margins.

Limited to US regional banking niche.

Minimal global impact.

Counterpoint

Micro‑cap banks remain vulnerable to rate volatility despite earnings beat.

Key entities

  • First Keystone Corp

    US‑listed regional bank (ticker FKYS).

Related articles

$FKYSMed

FIRST KEYSTONE ANNOUNCES THIRD QUARTER 2026 EARNINGS (UNAUDITED)

FIRST KEYSTONE CORP (FKYS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FIRST KEYSTONE ANNOUNCES THIRD QUARTER 2026 EARNINGS (UNAUDITED) ​ Berwick, Pennsylvania – October 30, 2026 - First Keystone Corporation (OTCID: FKYS), parent company of First Keystone Community Bank, reported an increase in total interest income of $3,195,000 or 5.6

$FKYSLow

FIRST KEYSTONE ANNOUNCES SECOND QUARTER 2026 EARNINGS (UNAUDITED)

FIRST KEYSTONE CORP (FKYS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FIRST KEYSTONE ANNOUNCES SECOND QUARTER 2026 EARNINGS (UNAUDITED) ​ Berwick, Pennsylvania – July 30, 2026 - First Keystone Corporation (OTCID: FKYS), parent company of First Keystone Community Bank, reported an increase in total interest income of $2,124,000 or 5.7%,

$PTHSMed

Pelthos (PTHS) Q3 2026 Earnings Call Transcript

Pelthos (PTHS) reported Q3 2026 net revenue of $15.2M, up 114% YoY, with Zelsuvmi treating 31,000 patients. Formulary coverage expanded to 70% of commercial lives. The company announced a deal with Castle Creek Biosciences, aiming to leverage synergies in dermatology and cell/gene therapy markets. Xepi and Xeglyze launches are planned for 2027.

$BMNRMedAI 8/10

Bitmine’s ($BMNR) $6.3 Billion Loss Highlights Overall Risks for Strategy ($MSTR) and Other Treasury Firms as MSCI Tightens Rules

Bitmine Immersion Technologies (BMNR) reported a $6.3B net loss for fiscal 2026, driven by $6.23B in unrealized losses on digital-asset holdings, primarily ether. The company held 5.9M ether tokens and 211 bitcoin at year-end. Operating revenue was $125M, with staking contributing 97%. MSCI's updated index rules may impact BMNR and other crypto-focused treasury firms, including Strategy (MSTR).

HighAI 8/10

Merck KGaA Earnings Call Signals Stronger Growth Ahead

Merck KGaA (MKKGY) reported Q3 earnings with accelerated growth, raised full-year guidance, and announced strategic investments. Key highlights include 5.1% organic sales growth, EUR 1.66B operating cash flow, and plans to acquire Silence Therapeutics. Management emphasized growth in biomanufacturing, semiconductors, and rare diseases, while noting Mavenclad's declining sales and softer demand in consumer electronics.